India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
He will be stationed at the company HQ in Bengaluru, India
Deal for 100 million doses with additional 100 million through 2023
Innovative solutions and a deep understanding of the market makes this a unique combination
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
AstraZeneca, Sinopharm and Moderna were part of the study
_logo_256_384.jpg){kind=logo}
It supports sequencing-based COVID 19 surveillance in India
It is designed to tackle mental health issues
Subscribe To Our Newsletter & Stay Updated
